Compare ESP & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | DTIL |
|---|---|---|
| Founded | 1928 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 197.9M |
| IPO Year | 1995 | 2019 |
| Metric | ESP | DTIL |
|---|---|---|
| Price | $62.15 | $6.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.40 |
| AVG Volume (30 Days) | 26.0K | ★ 219.8K |
| Earning Date | 09-23-2026 | 11-02-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | ★ 28.81 | N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | $46,124,325.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $13.61 | N/A |
| Revenue Next Year | $5.53 | N/A |
| P/E Ratio | $16.63 | ★ N/A |
| Revenue Growth | ★ 4.95 | N/A |
| 52 Week Low | $36.00 | $3.53 |
| 52 Week High | $74.77 | $9.62 |
| Indicator | ESP | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 35.77 |
| Support Level | $60.47 | $6.02 |
| Resistance Level | $67.31 | $7.65 |
| Average True Range (ATR) | 2.53 | 0.39 |
| MACD | -0.26 | -0.03 |
| Stochastic Oscillator | 33.73 | 19.81 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).